World

At least 6 dead in Japan as Typhoon Shanshan grinds on

Sep 01, 2024

Tokyo [Japan], September 1: At least six people were dead as Typhoon Shanshan crept eastward through Japan.
Drenching large areas with torrential rain, triggering landslide and flood warnings hundreds of kilometres from the storm's centre.
Footage on national broadcaster NHK showed homes with roofs partly sheered off while cars drove wheels-deep on flooded roads in the country's southwest. The storm made landfall in Kyushu on Thursday, bringing record levels of rainfall.
One person was missing and more than 100 have been injured, said Japan's Fire and Disaster Management Agency. More than 35,000 homes were without power in southern Kyushu's Kagoshima prefecture, according to Kyushu Electric.
Shanshan, centred in the Pacific Ocean some 480 km (300 miles) southwest of Tokyo at 12:50 p.m. (0350 GMT), triggered heavy rain as far away as the northernmost prefecture of Hokkaido, despite being downgraded to a tropical storm on Friday. Winds were gusting up to 25 metres per second (90 kph, 55 mph).
Authorities have issued flood and landslide warnings around the country since the storm's arrival, halting air and rail services and shutting factories.
The storm is forecast to weaken to a tropical depression over the weekend but is expected to continue to bring heavy rain, NHK reported.
Source: Fijian Broadcasting Cooperation

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025